A Post-Market Clinical Follow-up Study in Patients Treated With Vascular Grafts

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-12-06

Study Completion Date

2030-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The FLOWGRAFT post-market clinical follow-up study is undertaken to show the safety and performance of FlowWeave Bioseal, FlowNit Bioseal, FlowLine Bipore and FlowLine Bipore Heparin (combined named as Vascular Grafts) in the treatment of arterial diseases, such as dissection, aneurysm, intramural hematoma (IMH), penetrating aortic ulcer (PAU), contained rupture, stenosis in the aorta or peripheral arteries (lower limbs). This includes the use of FlowWeave Bioseal or FlowNit Bioseal for debranching of the head vessels in an alone standing procedure. Furthermore, it includes the use of the FlowLine Bipore and FlowLine Bipore Heparin Grafts as arterious-venous (AV) shunt.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Zenith Thoracic Alpha (ZTA) Post-Market Data Collection

NCT06094127

Thoracic Aortic Aneurysm Penetrating Aortic Ulcer

RECRUITING

Micronet Covered Stent in in Arterial Locations Beyond the Carotid Bifurcation - FLOW-Guard Study

NCT04461717

Peripheral Vascular Diseases

UNKNOWN

High Coverage CARotid Stenting vs. Medical Management Alone to Prevent EmboliSm From symptomaTic Non-stenotic cARotid Disease (SyNC)

NCT07166731

Carotid Artery Disease Symptomatic Carotid Artery Stenosis Carotid Artery Stenting +3 more

NOT_YET_RECRUITING

Evaluation of Efficacy of the EPIC™ Self-Expanding Nitinol Vascular Stent

NCT01336101

Peripheral Arterial Diseases Superficial Femoral Artery Stenosis

COMPLETED NA

A PMCF Study in Patients With Infrarenal Aortic Aneurysm Treated With the E-tegra Stent Graft System

NCT04765176

Vascular Aneurysm

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this study, patients who receive a Vascular Graft for the treatment of arterial diseases (aneurysm, PAU, IMH, dissection, stenosis) of the aorta or peripheral arteries (lower limbs) or as an AV shunt will be observed. This includes patients in whom the Vascular Grafts are used for debranching or reconstruction of the head vessels. Participating physicians will be asked to provide the observations, that were collected during routine care. Written informed consent, specifically allowing the use of clinical records for this observational study, will be obtained from every patient prior to data collection.

The period of data collection will be approximately 60 + 6 months (depending on the date of the last follow-up visit) from the date of intervention for each patient.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vascular Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Open repair

Open repair of the aorta and peripheral arteries

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Open repair of the aorta and peripheral arteries

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient ≥ 18 years at time of written informed consent
* Patient was selected for treatment with a commercially available Vascular Graft of JOTEC
* Patient satisfies at least one of the following categories:

* Acute (14 days) / subacute (15 - 90 days) dissection with double lumina in the aorta or peripheral artery / arteries (lower limb)
* Chronic (\>90 days) dissection with double lumina in the aorta or peripheral artery / arteries (lower limb)
* Aneurysm in the aorta or peripheral artery / arteries (lower limb)
* IMH in the aorta or peripheral artery / arteries (lower limb)
* PAU in the aorta or peripheral artery / arteries (lower limb)
* Contained rupture in the aorta or peripheral artery / arteries (lower limb)
* Stenosis in the aorta or peripheral artery / arteries (lower limb)
* Debranching of head vessels
* AV shunt
* Patient is willing and able to comply with all clinical study procedures and study visits.
* Patient has given written informed consent to participate in the study.

Exclusion Criteria

* Patient has any other medical, social, or psychological problem that in the opinion of the investigator preclude them from receiving this treatment, procedures, and evaluations pre- and post-procedure.
* Patient is scheduled for reconstruction of the tibial artery

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No